A Clinical Trial for CTD-ILD Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01424033|
Recruitment Status : Terminated (Departure of study team)
First Posted : August 26, 2011
Results First Posted : February 12, 2016
Last Update Posted : April 6, 2017
|Condition or disease||Intervention/treatment||Phase|
|Interstitial Lung Disease Connective Tissue Disease||Drug: N-Acetylcysteine||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Trial of Oral Medication for CTD-ILD Treatment|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||February 2013|
This is an open label trial, all patient will be entered into one treatment arm.
600mg by mouth, three times daily for 12 months
- Pulmonary Function Tests [ Time Frame: Every 3 months ]Not recorded. Study terminated due to departure of PI.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01424033
|United States, Michigan|
|University of Michigan|
|Ann Arbor, Michigan, United States, 48109|